Related Experiment Video

Updated: Jun 2, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Cox-2 gene polymorphism and IL-6 levels in coronary artery disease

K K Ol1, B Agachan, U Gormus

  • 1Department of Molecular Medicine, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey.

Genetics and Molecular Research : GMR
|May 17, 2011
PubMed

Insights

The study found a specific gene variant (GG genotype) in the Cox-2 enzyme is linked to a higher risk of coronary artery disease, especially in patients with diabetes. This genetic factor was also associated with lower interleukin-6 levels.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Immunology

Background:

  • Coronary artery disease (CAD) is a leading cause of death, with diabetes mellitus as a major risk factor.
  • Atherosclerosis, a key complication, is an inflammatory process involving prostaglandins and interleukins.
  • The role of Cox-2 polymorphism and interleukin-6 in CAD, particularly in relation to diabetes, requires further investigation.

Purpose of the Study:

  • To investigate the association between Cox-2 (-765G > C) polymorphism and interleukin-6 (IL-6) levels in patients with coronary artery disease.
  • To compare these factors in patients with and without diabetes mellitus.
  • To determine the risk associated with specific Cox-2 genotypes in CAD development.

Main Methods:

  • Case-control study comparing CAD patients and healthy controls.
  • Genotyping for Cox-2 (-765G > C) polymorphism.
  • Measurement of serum interleukin-6 levels.
  • Stratification of patients into diabetic and non-diabetic groups.

Main Results:

  • The GG allele frequency of Cox-2 (-765G > C) polymorphism was significantly higher in the CAD patient group compared to controls.
  • Individuals with the GG genotype exhibited an approximately 2.78-fold increased risk of coronary artery disease.
  • A significant association was observed between Cox-2 (-765G > C) polymorphism and lower interleukin-6 levels, with levels decreasing in the order GG > GC > CC.

Conclusions:

  • The Cox-2 (-765G > C) polymorphism, specifically the GG genotype, is a significant risk factor for coronary artery disease.
  • This genetic predisposition may be exacerbated by diabetes mellitus.
  • The observed inverse relationship between Cox-2 polymorphism and IL-6 levels suggests complex inflammatory pathways in CAD pathogenesis.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...